MS
MSK.F MicroPort Scientific Corporation
- Market cap
- EUR 1.24B
- P/E
- -
- P/B
- 1.42x
- ROE
- 4.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MSK.F undervalued?
Graham numberThe Graham number of MicroPort Scientific Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MicroPort Scientific Corporation fundamental analysis
No fundamental analysis for MicroPort Scientific Corporation yet.
MicroPort Scientific Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and…
Full company profileMicroPort Scientific Corporation financial statements
MicroPort Scientific Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 390M | 444M | 669M | 793M | 649M | 779M | 841M | 951M | 924M | 995M |
| Gross Profit | 272M | 318M | 470M | 564M | 436M | 492M | 502M | 532M | 496M | 554M |
| Operating Income | 37.7M | 62.2M | 48.3M | 25.1M | -167M | -339M | -480M | -375M | -159M | -54.6M |
| EBITDA | - | 78.2M | 95.1M | 146M | -176M | -201M | -366M | -383M | -5.61M | 23.9M |
| Net Income | 14.1M | 18.8M | 23.9M | 46.3M | -191M | -276M | -437M | -478M | -214M | 48.5M |
| EPS | - | 0.01 | 0.01 | 0.03 | -0.11 | -0.15 | -0.24 | -0.26 | -0.12 | 0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 775M | 904M | 1.27B | 1.60B | 2.47B | 4.38B | 3.99B | 3.93B | 3.63B | 3.70B |
| Total Liabilities | 428M | 464M | 746M | 944M | 1.08B | 2.16B | 2.20B | 2.53B | 2.49B | 2.20B |
| Shareholders' Equity | 333M | 402M | 443M | 519M | 1.13B | 1.49B | 1.14B | 758M | 603M | 981M |
| Cash & Short-term Investments | 124M | 160M | 130M | 280M | 1.00B | 1.75B | 1.20B | 1.02B | 713M | 683M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 82.5M | 97.2M | 84.1M | 26.5M | -23.2M | -258M | -343M | -232M | -49.7M | 69.1M |
| Capital Expenditure | 65.7M | 58.0M | 68.6M | 97.0M | 104M | 222M | 235M | 199M | 108M | 102M |
| Free Cash Flow | - | 19.0M | -5.97M | -88.6M | -144M | -505M | -601M | -431M | -158M | -32.6M |
| Ratios | ||||||||||
| ROE | 4.2% | 4.7% | 5.4% | 8.9% | -17.0% | -18.5% | -38.5% | -63.0% | -35.5% | 4.9% |
| ROA | 1.8% | 2.1% | 1.9% | 2.9% | -7.7% | -6.3% | -10.9% | -12.1% | -5.9% | 1.3% |
| Net Profit Margin | 3.6% | 4.2% | 3.6% | 5.8% | -29.5% | -35.5% | -51.9% | -50.2% | -23.2% | 4.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MicroPort Scientific Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 28, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 6.42M | 0.00 | - |
| 2020 | USD 6.66M | 0.00 | - |
| 2019 | EUR 3.43M | 0.00 | 7.4% |
| 2018 | EUR 3.58M | 0.00 | 15.0% |
| 2017 | EUR 2.30M | 0.00 | 12.2% |
| 2016 | EUR 2.30M | - | 16.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MicroPort Scientific Corporation
- Insiders 31.97%
- Institutions 9.72%
- Public & others 58.32%
- Shares outstanding 1.91B
- Free float 1.12B
MicroPort Scientific Corporation company profile
- Company name
- MicroPort Scientific Corporation
- Ticker
- MSK.F
- ISIN
- KYG608371046
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,547
- Fiscal year end
- December
- Address
- 1601 Zhangdong Road, Shanghai, China, 201203
- Phone
- 86 21 3895 4600
- Website
- microport.com
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and active devices. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma products, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers. Its Endovascular and Peripheral Vascular Devices segment provides disease solutions for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection aneurysms, and other arteriovenous related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for cerebrovascular diseases. The company's Surgical Robot Business segment offers surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Structural Heart Disease Business segment provides heart valve devices. It is also involved in the distribution of medical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.
MicroPort Scientific Corporation management
10- Mr. Jonathan W. ChenCEO & Executive Director · born 1975
- Dr. Zhaohua Chang Ph.D.Founder & Chief Scientific Officer · born 1963
- Mr. Hongbin Sun C.F.A.Chief Financial Officer · born 1975
- Dr. Jie Zhang Ph.D.Chief Technology Officer · born 1979
- Ms. He LiBoard Secretary & Senior VP of Securities and Legal Affairs
- Mr. Junder ChiangChief Human Resources Officer · born 1965
- Mr. Yimin XuSenior EVP of Regulatory Affairs & Property Management of MicroPort Sinica Co., Ltd · born 1967
- Mr. Lei JiangCo-Chairperson & Chief Marketing Officer - China Executive Committee · born 1978
- Mr. Yiyun QueEVP of Intelligent Manufacturing & Global Supply Chain of MicroPort Sinica Co., Ltd.
- Mr. Tianbai YuPresident of MicroPort Orthopedics China & Head of Global Supply Chain of Orthopedics